Obinutuzumab patent expiry germany?

When does obinutuzumab’s patent protection expire in Germany?

For Germany, the exact “patent expiry” date for obinutuzumab depends on which form of exclusivity you mean: the underlying patents, and the later period of regulatory exclusivity (if any) that can extend market protection even after a primary patent ends. The provided information does not include the relevant obinutuzumab patent numbers or the German/EP decision details needed to state a specific expiry date.

Which patents or rights usually control market exclusivity for obinutuzumab in Germany?

In Germany (and across Europe), market access for an antibody drug like obinutuzumab can be tied to a mix of:
- Patent claims covering the drug substance, formulations, and/or specific therapeutic uses.
- Supplementary protection certificates (SPCs), where available, which can extend protection beyond the base patent term.
- Regulatory exclusivity periods tied to first marketing authorization and additional data protection rules.

Without the specific patent/SCP/SPC identifiers for obinutuzumab in Germany, it’s not possible to map “expiry” to a single date from the information provided.

How can you look up the exact obinutuzumab expiry date for Germany?

To get a reliable Germany-specific expiry date, you typically need to check patent/SPC status for obinutuzumab in the relevant jurisdiction(s), then translate that into Germany’s effective protection window. Practical sources include:
- The European Patent Register / Espacenet for the underlying European patents and their validated countries (including Germany).
- German or European SPC registers (to see whether an SPC was granted and its end date).
- National commercial “patent expiry” tools that list the active German protection periods by brand and product form.

If you share the brand name you mean (e.g., by its commercial product in Germany) and the relevant patent identifiers (or a link you found), I can help interpret which date is the one users mean (base patent vs SPC vs exclusivity).

Does “patent expiry” mean biosimilar entry is immediate in Germany?

Not always. Even if a primary patent expires, biosimilar entry can still be blocked by:
- Remaining patents covering other claims (different therapeutic indications, methods of treatment, or manufacturing aspects).
- Active litigation or injunctions.
- Residual data/regulatory exclusivity rules that delay reimbursement and/or marketing authorization timing in practice.

So an “expiry” date alone doesn’t guarantee the earliest launch date in Germany.

Is obinutuzumab already affected by biosimilar competition in Europe?

Biosimilar timing depends on (1) when the legal barriers clear in the relevant territories and (2) whether there are still blocking patents or injunctions. Determining this requires the latest status of the relevant German/EU protection and any post-grant litigation, which isn’t included in the provided information.

What I need from you to give a specific Germany date

Send any one of the following and I can provide the exact expiry date(s) in Germany and explain what each one means:
1. The obinutuzumab product you mean in Germany (brand/manufacturer) plus any patent/SPC number you found.
2. A link to a patent/SPC listing page you’re using.
3. The European patent number(s) and whether an SPC was granted.

Sources

No sources were provided with your question, so I can’t cite a verified Germany-specific expiry date.